Bruce Williams, Interim Chairman

Bruce Williams has significant operational experience in the biopharmaceutical industry and has held senior leadership positions at both large pharmaceutical firms and start-up biotechs. He served as Senior Vice President, Global Business Management at Enzon Pharmaceuticals, where he led the company’s commercial functions. Prior to that, he was Senior Vice President, Sales & Marketing at Genta Incorporated, where he built and led the sales and marketing function and negotiated a licensing and co-development/co-marketing agreement with Aventis for the company’s lead product. He was previously Vice President of Sales & Marketing at Celgene Corporation, where he built the company’s commercial and distribution infrastructure to support the launch of its first product, Thalomid (thalidomide). Earlier in his career, Mr. Williams was Executive Director, Marketing at Ortho Biotech (subsidiary of Johnson & Johnson), where he led the marketing of Procrit (epoetin alfa) from pre-approval through its first year of $1 billion in sales. In addition to Motif Bio, Mr. Williams currently serves on the board of Afaxys Incorporated. He also serves on the Board of Trustees of Rutgers Preparatory School and is Treasurer and Trustee of the Independent School Chair Association. He holds an MBA from Columbia University and a Bachelor of Arts degree in biology from Syracuse University.

Jonathan E. Gold, Interim Chief Financial Officer

Jonathan E. Gold has a history of senior financial positions and is currently Managing Director of JEG Capital Partners LLC, a family office and asset manager. He previously was a portfolio manager for the Federated Kaufmann Funds. Prior to that, Mr. Gold was a venture capitalist and was active in financing and building life sciences and technology companies. Mr. Gold received his B.S. and MBA in Finance from New York University’s Stern School of Business.

Graham Lumsden, Chief Executive Officer, Director

Graham Lumsden, Chief Executive Officer of Motif, is responsible for all aspects of the strategy, management, and operations of the Company. Prior to joining Motif, Mr. Lumsden was Worldwide Business Leader, Contraceptives and Osteoporosis at Merck & Co., Inc. where he previously held other international senior leadership roles as well as senior marketing positions. Mr. Lumsden has a proven record of success leading change and delivering results at Worldwide Vice President level including cross-functional team leadership, new product launches, pre-clinical / clinical development, regulatory strategy, IP strategy / litigation, and domestic / international sales and marketing. Mr. Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS), holds a masters from the Chartered Institute of Marketing (MCIM), and is a dual citizen of the U.S. and UK.